Ana Filipa Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ana Filipa Costa has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Catarina Gomes
Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal
3 shared publications - Celso Albuquerque Reis
i3S ‐ Instituto de Investigação e Inovação em Saúde Universidade do Porto Porto Portugal
3 shared publications - Miguel Silva-Ramos
Unidade Local de Saúde de Santo António, Porto, Portugal.
3 shared publications - Paulo Correia-De-Sá
Laboratório de Farmacologia e Neurobiologia, Center for Drug Discovery and Innovative Medicines (MedInUP)/RISE-Health: Health Research Network, Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto (ICBAS-UP) 2
3 shared publications - Cátia Vieira
Laboratório de Farmacologia e Neurobiologia/MedInUP, Instituto de Ciências Biomédicas Abel Salazar—Universidade do Porto (ICBAS-UP), 4050-313 Porto, Portugal
2 shared publications Diana Campos
I3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal; IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal
2 shared publications
Latest Publications
- Open Access
- 19 April 2023
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 40 (4) , 421-433
ST3GalIV drives SLeX biosynthesis in gastrointestinal cancer cells and associates with cancer cell motility
Expression of sialyl Lewis X (SLeX) is a well-documented event during malignant transformation of cancer cells, and largely associates with their invasive and metastatic properties. Glycoproteins and glycolipids are the main carriers of SLeX, whose biosynthesis is known to be performed by different glycosyltransferases, namely by the family of β-galactoside-α2,3-sialyltransferases (ST3Gals). In this study, we sought to elucidate the role of ST3GalIV in the biosynthesis of SLeX and in malignant properties of gastrointestinal (GI) cancer cells. By immunofluorescent screening, we selected SLeX-positive GI cancer cell lines and silenced ST3GalIV expression via CRISPR/Cas9. Flow cytometry, immunofluorescence and western blot analysis showed that ST3GalIV KO efficiently impaired SLeX expression in most cancer cell lines, with the exception of the colon cancer cell line LS174T. The impact of ST3GalIV KO in the biosynthesis of SLeX isomer SLeA and non sialylated Lewis X and A were also evaluated and overall, ST3GalIV KO led to a decreased expression of SLeA and an increased expression in both LeX and LeA. In addition, the abrogation of SLeX on GI cancer cells led to a reduction in cell motility. Furthermore, ST3GalVI KO was performed in LS174T ST3GalIV KO cells, resulting in the complete abolishment of SLeX expression and consequent reduced motility capacity of those cells. Overall, these findings portray ST3GalIV as the main, but not the only, enzyme driving the biosynthesis of SLeX in GI cancer cells, with a functional impact on cancer cell motility.
- 19 April 2023
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 40 (4) , 421-433
Open AccessST3GalIV drives SLeX biosynthesis in gastrointestinal cancer cells and associates with cancer cell motility
Expression of sialyl Lewis X (SLeX) is a well-documented event during malignant transformation of cancer cells, and largely associates with their invasive and metastatic properties. Glycoproteins and glycolipids are the main carriers of SLeX, whose biosynthesis is known to be performed by different glycosyltransferases, namely by the family of β-galactoside-α2,3-sialyltransferases (ST3Gals). In this study, we sought to elucidate the role of ST3GalIV in the biosynthesis of SLeX and in malignant properties of gastrointestinal (GI) cancer cells. By immunofluorescent screening, we selected SLeX-positive GI cancer cell lines and silenced ST3GalIV expression via CRISPR/Cas9. Flow cytometry, immunofluorescence and western blot analysis showed that ST3GalIV KO efficiently impaired SLeX expression in most cancer cell lines, with the exception of the colon cancer cell line LS174T. The impact of ST3GalIV KO in the biosynthesis of SLeX isomer SLeA and non sialylated Lewis X and A were also evaluated and overall, ST3GalIV KO led to a decreased expression of SLeA and an increased expression in both LeX and LeA. In addition, the abrogation of SLeX on GI cancer cells led to a reduction in cell motility. Furthermore, ST3GalVI KO was performed in LS174T ST3GalIV KO cells, resulting in the complete abolishment of SLeX expression and consequent reduced motility capacity of those cells. Overall, these findings portray ST3GalIV as the main, but not the only, enzyme driving the biosynthesis of SLeX in GI cancer cells, with a functional impact on cancer cell motility.
- Top Cited PapersOpen Access
- 1 September 2020
- Published by Elsevier in Trends in Cancer
- Vol. 6 (9) , 757-766
Targeting Glycosylation: A New Road for Cancer Drug Discovery
- 1 September 2020
- Published by Elsevier in Trends in Cancer
- Vol. 6 (9) , 757-766
Top Cited PapersOpen AccessTargeting Glycosylation: A New Road for Cancer Drug Discovery
- Open Access
- 12 November 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (7) , 1589-1608
β3 Adrenoceptor‐induced cholinergic inhibition in human and rat urinary bladders involves the exchange protein directly activated by cyclic AMP 1 favoring adenosine release
Background and Purpose The mechanism by which β3 receptor agonists (e.g. mirabegron) control bladder overactivity may involve adenosine release from human and rat detrusor smooth muscle. Retrograde activation of adenosine A1 receptors reduces ACh release from cholinergic bladder nerves. β3‐Adrenoceptors usually couple to adenylyl cyclase. Here we investigated, which of the cAMP targets, protein kinase A or the exchange protein directly activated by cAMP (EPAC) could be involved in this cholinergic inhibition of the bladder. Experimental Approach [3H]ACh and adenosine release from urothelium‐denuded detrusor strips of cadaveric human organ donors and rats were measured by liquid scintillation spectrometry and HPLC, respectively. In vivo cystometry was also performed in urethane‐anaesthetized rats. Key Results The exchange protein directly activated by cAMP (EPAC) inhibitor, ESI‐09, prevented mirabegron‐ and isoprenaline‐induced adenosine release from human and rat detrusor strips respectively. ESI‐09, but not the PKA inhibitor, H‐89, attenuated inhibition of [3H]ACh release from stimulated (10 Hz) detrusor strips caused by activating β3‐adrenoceptors, AC (forskolin) and EPAC1 (8‐CTP‐2Me‐cAMP). Isoprenaline‐induced inhibition of [3H]ACh release was also prevented by inhibitors of PKC (chelerythrine and Go6976) and of the equilibrative nucleoside transporter 1 (ENT1; dipyridamole and NBTI), but not by PLC inhibition with U73122. Pretreatment with ESI‐09, but not with H‐89, prevented the reduction of the voiding frequency caused by isoprenaline and forskolin in vivo. Conclusion and Implications Data suggest that β3‐adrenoceptor‐induced inhibition of cholinergic neurotransmission in human and rat urinary bladders involves activation of an EPAC1/PKC pathway downstream cAMP production resulting in adenosine outflow via ENT1.
- 12 November 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (7) , 1589-1608
Open Accessβ3 Adrenoceptor‐induced cholinergic inhibition in human and rat urinary bladders involves the exchange protein directly activated by cyclic AMP 1 favoring adenosine release
Background and Purpose The mechanism by which β3 receptor agonists (e.g. mirabegron) control bladder overactivity may involve adenosine release from human and rat detrusor smooth muscle. Retrograde activation of adenosine A1 receptors reduces ACh release from cholinergic bladder nerves. β3‐Adrenoceptors usually couple to adenylyl cyclase. Here we investigated, which of the cAMP targets, protein kinase A or the exchange protein directly activated by cAMP (EPAC) could be involved in this cholinergic inhibition of the bladder. Experimental Approach [3H]ACh and adenosine release from urothelium‐denuded detrusor strips of cadaveric human organ donors and rats were measured by liquid scintillation spectrometry and HPLC, respectively. In vivo cystometry was also performed in urethane‐anaesthetized rats. Key Results The exchange protein directly activated by cAMP (EPAC) inhibitor, ESI‐09, prevented mirabegron‐ and isoprenaline‐induced adenosine release from human and rat detrusor strips respectively. ESI‐09, but not the PKA inhibitor, H‐89, attenuated inhibition of [3H]ACh release from stimulated (10 Hz) detrusor strips caused by activating β3‐adrenoceptors, AC (forskolin) and EPAC1 (8‐CTP‐2Me‐cAMP). Isoprenaline‐induced inhibition of [3H]ACh release was also prevented by inhibitors of PKC (chelerythrine and Go6976) and of the equilibrative nucleoside transporter 1 (ENT1; dipyridamole and NBTI), but not by PLC inhibition with U73122. Pretreatment with ESI‐09, but not with H‐89, prevented the reduction of the voiding frequency caused by isoprenaline and forskolin in vivo. Conclusion and Implications Data suggest that β3‐adrenoceptor‐induced inhibition of cholinergic neurotransmission in human and rat urinary bladders involves activation of an EPAC1/PKC pathway downstream cAMP production resulting in adenosine outflow via ENT1.
- 10 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (8) , e3083
ß3-adrenoceptor inhibition of cholinergic bladder nerves requires retrograde adenosine release triggered by EPAC/PKC/ENT1 pathway in the human and rat detrusor
- 10 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (8) , e3083
ß3-adrenoceptor inhibition of cholinergic bladder nerves requires retrograde adenosine release triggered by EPAC/PKC/ENT1 pathway in the human and rat detrusor
- Open Access
- 1 January 2019
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (24) , 7431-7446
Carcinoembryonic antigen carrying SLeX as a new biomarker of more aggressive gastric carcinomas
Malignant transformation of gastric cells is accompanied by the deregulated expression of glycosyltransferases leading to the biosynthesis of tumor-associated glycans such as the sialyl-Lewis X antigen (SLex). SLex presence on cell surface glycoconjugates increases the invasive capacity of gastric cancer cells and is associated with tumor metastasis. ST3Gal IV enzyme is involved in the synthesis of SLex antigen and overexpressed in gastric carcinomas. Herein, we identified the glycoproteins carrying SLex in gastric cancer cells overexpressing ST3Gal IV enzyme and evaluated their biomarker potential for gastric carcinoma.
- 1 January 2019
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (24) , 7431-7446
Open AccessCarcinoembryonic antigen carrying SLeX as a new biomarker of more aggressive gastric carcinomas
Malignant transformation of gastric cells is accompanied by the deregulated expression of glycosyltransferases leading to the biosynthesis of tumor-associated glycans such as the sialyl-Lewis X antigen (SLex). SLex presence on cell surface glycoconjugates increases the invasive capacity of gastric cancer cells and is associated with tumor metastasis. ST3Gal IV enzyme is involved in the synthesis of SLex antigen and overexpressed in gastric carcinomas. Herein, we identified the glycoproteins carrying SLex in gastric cancer cells overexpressing ST3Gal IV enzyme and evaluated their biomarker potential for gastric carcinoma.
- 1 August 2017
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 313 (2) , F388-F403
Inhibition of cholinergic neurotransmission by β3-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders
The direct detrusor relaxant effect of β3-adrenoceptor agonists as a primary mechanism to improve overactive bladder symptoms has been questioned. Among other targets, activation of β3-adrenoceptors downmodulate nerve-evoked acetylcholine (ACh) release, but there is insufficient evidence for the presence of these receptors on bladder cholinergic nerve terminals. Our hypothesis is that adenosine formed from the catabolism of cyclic AMP in the detrusor may act as a retrograde messenger via prejunctional A1receptors to explain inhibition of cholinergic activity by β3-adrenoceptors. Isoprenaline (1 µM) decreased [3H]ACh release from stimulated (10 Hz, 200 pulses) human (−47 ± 5%) and rat (−38 ± 1%) detrusor strips. Mirabegron (0.1 µM, −53 ± 8%) and CL316,243 (1 µM, −37 ± 7%) mimicked isoprenaline (1 µM) inhibition, and their effects were prevented by blocking β3-adrenoceptors with L748,337 (30 nM) and SR59230A (100 nM), respectively, in human and rat detrusor. Mirabegron and isoprenaline increased extracellular adenosine in the detrusor. Blockage of A1receptors with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 100 nM) or the equilibrative nucleoside transporters (ENT) with dipyridamole (0.5 µM) prevented mirabegron and isoprenaline inhibitory effects. Dipyridamole prevented isoprenaline-induced adenosine outflow from the rat detrusor, and this effect was mimicked by the ENT1 inhibitor, S-(4-nitrobenzyl)-6-thioinosine (NBTI, 30 µM). Cystometry recordings in anesthetized rats demonstrated that SR59230A, DPCPX, dipyridamole, and NBTI reversed the decrease in the voiding frequency caused by isoprenaline (0.1–1,000 nM). Data suggest that inhibition of cholinergic neurotransmission by β3-adrenoceptors results from adenosine release via equilibrative nucleoside transporters and prejunctional A1-receptor stimulation in human and rat urinary bladder.
- 1 August 2017
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 313 (2) , F388-F403
Inhibition of cholinergic neurotransmission by β3-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders
The direct detrusor relaxant effect of β3-adrenoceptor agonists as a primary mechanism to improve overactive bladder symptoms has been questioned. Among other targets, activation of β3-adrenoceptors downmodulate nerve-evoked acetylcholine (ACh) release, but there is insufficient evidence for the presence of these receptors on bladder cholinergic nerve terminals. Our hypothesis is that adenosine formed from the catabolism of cyclic AMP in the detrusor may act as a retrograde messenger via prejunctional A1receptors to explain inhibition of cholinergic activity by β3-adrenoceptors. Isoprenaline (1 µM) decreased [3H]ACh release from stimulated (10 Hz, 200 pulses) human (−47 ± 5%) and rat (−38 ± 1%) detrusor strips. Mirabegron (0.1 µM, −53 ± 8%) and CL316,243 (1 µM, −37 ± 7%) mimicked isoprenaline (1 µM) inhibition, and their effects were prevented by blocking β3-adrenoceptors with L748,337 (30 nM) and SR59230A (100 nM), respectively, in human and rat detrusor. Mirabegron and isoprenaline increased extracellular adenosine in the detrusor. Blockage of A1receptors with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 100 nM) or the equilibrative nucleoside transporters (ENT) with dipyridamole (0.5 µM) prevented mirabegron and isoprenaline inhibitory effects. Dipyridamole prevented isoprenaline-induced adenosine outflow from the rat detrusor, and this effect was mimicked by the ENT1 inhibitor, S-(4-nitrobenzyl)-6-thioinosine (NBTI, 30 µM). Cystometry recordings in anesthetized rats demonstrated that SR59230A, DPCPX, dipyridamole, and NBTI reversed the decrease in the voiding frequency caused by isoprenaline (0.1–1,000 nM). Data suggest that inhibition of cholinergic neurotransmission by β3-adrenoceptors results from adenosine release via equilibrative nucleoside transporters and prejunctional A1-receptor stimulation in human and rat urinary bladder.